



Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II

SAFETY DATA SHEET

Superconcentrate Protector F1 Box

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : Superconcentrate Protector F1 Box
Product code : 56700
Product description : Not available.
Product type : Liquid.

1.2 Relevant identified uses of the substance or mixture and uses advised against

Restricted to professional users.

1.3 Details of the supplier of the safety data sheet

Alpha, Alent plc
Forsyth Road
Sheerwater
Woking
Surrey
England
GU21 5RZ
Tel: +44(0)1483 758400
Fax: +44(0)1483 728837

Manufacturer

Alpha, Alent plc
Koenendelseweg 29
5222 BG
's-Hertogenbosch
The Netherlands
Tel: +31 73 6280 111
Fax: +31 73 6219 283

Contact person : shosken@alent.com

Emergency phone:

Material uses : Water treatment agent.

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Directive 1999/45/EC [DPD]

Europe

☒ The product is classified as dangerous according to Directive 1999/45/EC and its amendments.

Classification : ☒ Xi; R36

Human health hazards : ☒ Irritating to eyes.

Denmark

☒ The product is classified as dangerous according to Directive 1999/45/EC and its amendments.

Classification : ☒ Xi; R36

Human health hazards : ☒ Irritating to eyes.

Norway

Superconcentrate Protector F1 Box**SECTION 2: Hazards identification**

The product is classified as dangerous according to Directive 1999/45/EC and its amendments.

Classification : Xi, R36

Human health hazards : Irritating to eyes.

See Section 16 for the full text of the R phrases or H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard symbol or symbols :



Indication of danger : Irritant

Risk phrases : R36- Irritating to eyes.

Safety phrases : S2- Keep out of the reach of children.
S46- If swallowed, seek medical advice immediately and show this container or label.

Hazardous ingredients :

Supplemental label elements : Safety data sheet available for professional user on request.

2.3 Other hazards

Other hazards which do not result in classification : None known.

SECTION 3: Composition/information on ingredients

Substance/mixture : Mixture

Product/ingredient name	Identifiers	%	Classification		Type
			67/548/EEC	Regulation (EC) No. 1272/2008 [CLP]	
Europe					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1]
			See Section 16 for the full text of the R-phrases declared above.	See Section 16 for the full text of the H-statements declared above.	
Austria					

Superconcentrate Protector F1 Box**SECTION 3: Composition/information on ingredients**

2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Belgium					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Bulgaria					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn	[1]

Superconcentrate Protector F1 Box

SECTION 3: Composition/information on ingredients

molybdenum trioxide	EC: *601-707-2 CAS: 12045-78-2 REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	child) (oral) Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Croatia					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
propane-1,2-diol	REACH #: 01-2119456809-23 EC: 200-338-0 CAS: 57-55-6	>=1 - <5	Not classified.	Not classified.	-
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Czech Republic					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Denmark					

Superconcentrate Protector F1 Box**SECTION 3: Composition/information on ingredients**

2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Estonia					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1]
Finland					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20	>=3 - <5	Xn; R22 Xi; R36	Acute Tox. 4, H302 Eye Irrit. 2, H319	[1]

Superconcentrate Protector F1 Box

SECTION 3: Composition/information on ingredients

Boron potassium oxide (B4K2O7), tetrahydrate	EC: 202-394-1 CAS: 95-14-7 REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	R52/53 Repr. Cat. 3; R63	Aquatic Chronic 3, H412 Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
France					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1]
Germany					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1]
Greece					

Superconcentrate Protector F1 Box**SECTION 3: Composition/information on ingredients**

2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Hungary					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Ireland					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
propane-1,2-diol	REACH #: 01-2119456809-23 EC: 200-338-0 CAS: 57-55-6	>=1 - <5	Not classified.	Not classified.	[2]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn	[1]

Superconcentrate Protector F1 Box

SECTION 3: Composition/information on ingredients

molybdenum trioxide	EC: *601-707-2 CAS: 12045-78-2 REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	child) (oral) Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Italy					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1]
Latvia					
sebacic acid	REACH #: 01-2119519212-52 EC: 203-845-5 CAS: 111-20-6	>=15 - <20	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1] [2]
propane-1,2-diol	REACH #: 01-2119456809-23 EC: 200-338-0 CAS: 57-55-6	>=1 - <5	Not classified.	Not classified.	[2]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1]
Lithuania					

Superconcentrate Protector F1 Box

SECTION 3: Composition/information on ingredients

2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
sebacic acid	REACH #: 01-2119519212-52 EC: 203-845-5 CAS: 111-20-6	>=15 - <20	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
propane-1,2-diol	REACH #: 01-2119456809-23 EC: 200-338-0 CAS: 57-55-6	>=1 - <5	Not classified.	Not classified.	[2]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Netherlands					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1]
Norway					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318	[1] [2]

Superconcentrate Protector F1 Box

SECTION 3: Composition/information on ingredients

benzotriazole	CAS: 111-42-2 Index: 603-071-00-1 REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	STOT RE 2, H373 (oral) Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
propane-1,2-diol	REACH #: 01-2119456809-23 EC: 200-338-0 CAS: 57-55-6	>=1 - <5	Not classified.	Not classified.	[2]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Poland					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Portugal					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #:	>=0.1 -	Carc. Cat. 3; R40	Eye Irrit. 2, H319	[1] [2]

Superconcentrate Protector F1 Box

SECTION 3: Composition/information on ingredients

	01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	<1	Xi; R36/37	Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	
Romania					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Slovakia					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
2-Propenoic acid, homopolymer, sodium salt	CAS: 9003-04-7	>=1 - <5	Not classified.	Not classified.	[2]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Slovenia					
2,2',2''-nitritotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373	[1] [2]

Superconcentrate Protector F1 Box

SECTION 3: Composition/information on ingredients

benzotriazole	Index: 603-071-00-1 REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	(oral) Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1]
Spain					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Sweden					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide	REACH #:	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd	[1]

Superconcentrate Protector F1 Box**SECTION 3: Composition/information on ingredients**

(B4K2O7), tetrahydrate	01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2			(Fertility and Unborn child) (oral)	
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Switzerland					
2,2',2''-nitrilotriethanol	REACH #: 01-2119486482-31 EC: 203-049-8 CAS: 102-71-6	>=25 - <35	Not classified.	Not classified.	[2]
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]
Turkey					
2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1] [2]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1]
United Kingdom (UK)					

Superconcentrate Protector F1 Box**SECTION 3: Composition/information on ingredients**

2,2'-iminodiethanol	REACH #: 01-2119488930-28 EC: 203-868-0 CAS: 111-42-2 Index: 603-071-00-1	>=5 - <7	Xn; R22, R48/22 Xi; R41, R38	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT RE 2, H373 (oral)	[1]
benzotriazole	REACH #: 01-2119979079-20 EC: 202-394-1 CAS: 95-14-7	>=3 - <5	Xn; R22 Xi; R36 R52/53	Acute Tox. 4, H302 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	[1]
propane-1,2-diol	REACH #: 01-2119456809-23 EC: 200-338-0 CAS: 57-55-6	>=1 - <5	Not classified.	Not classified.	[2]
Boron potassium oxide (B4K2O7), tetrahydrate	REACH #: 01-2119970730-37 EC: *601-707-2 CAS: 12045-78-2	<6.8	Repr. Cat. 3; R63	Repr. 2, H361fd (Fertility and Unborn child) (oral)	[1]
molybdenum trioxide	REACH #: 01-2119488038-30 EC: 215-204-7 CAS: 1313-27-5 Index: 042-001-00-9	>=0.1 - <1	Carc. Cat. 3; R40 Xi; R36/37	Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H335 (Respiratory tract irritation)	[1] [2]

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII

[4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

[5] Substance of equivalent concern

SECTION 4: First aid measures**4.1 Description of first aid measures****Eye contact**

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.

Inhalation

: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Skin contact

: Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing before reuse. Clean shoes thoroughly before reuse.

SECTION 4: First aid measures

- Ingestion** : Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effects

- Eye contact** : Irritating to eyes.
- Inhalation** : Exposure to decomposition products may cause a health hazard. Serious effects may be delayed following exposure.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

Over-exposure signs/symptoms

- Eye contact** : Adverse symptoms may include the following:
irritation
watering
redness
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Specific treatments** : No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : None known.

5.2 Special hazards arising from the substance or mixture

- Hazards from the substance or mixture** : In a fire or if heated, a pressure increase will occur and the container may burst.
- Hazardous combustion products** : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
nitrogen oxides
metal oxide/oxides

5.3 Advice for firefighters

- Special precautions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

SECTION 5: Firefighting measures

- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** :  No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
- For emergency responders** : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also Section 8 for additional information on hygiene measures.

- 6.2 Environmental precautions** : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and materials for containment and cleaning up

- Small spill** :  Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
- Large spill** :  Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.

- 6.4 Reference to other sections** : See Section 1 for emergency contact information.
See Section 8 for information on appropriate personal protective equipment.
See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

- Protective measures** :  Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapour or mist. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

SECTION 7: Handling and storage**7.2 Conditions for safe storage, including any incompatibilities**

: Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

7.3 Specific end use(s)

Recommendations : Not available.

Industrial sector specific solutions : Not available.

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

8.1 Control parameters**Occupational exposure limits**

Product/ingredient name	Exposure limit values
Europe No exposure limit value known.	
Austria  2,2',2''-nitrilotriethanol	GKV_MAK (Austria, 12/2011). Skin sensitiser. PEAK: 1.6 ppm, 4 times per shift, 15 minutes. Form: Inhalable fraction TWA: 0.8 ppm 8 hours. Form: Inhalable fraction PEAK: 10 mg/m ³ , 4 times per shift, 15 minutes. Form: inhalable fraction TWA: 5 mg/m ³ 8 hours. Form: inhalable fraction
2,2'-iminodiethanol	GKV_MAK (Austria, 9/2007). Absorbed through skin. Skin sensitiser. STEL: 4 mg/m ³ , 4 times per shift, 15 minutes. STEL: 0.92 ppm, 4 times per shift, 15 minutes. TWA: 2 mg/m ³ 8 hours. TWA: 0.46 ppm 8 hours.
molybdenum trioxide	GKV_MAK (Austria, 12/2011). Notes: measured as Mo PEAK: 20 mg/m ³ , (measured as Mo), 2 times per shift, 60 minutes. Form: inhalable fraction TWA: 10 mg/m ³ , (measured as Mo) 8 hours. Form: inhalable fraction
Belgium  2,2',2''-nitrilotriethanol	Lijst Grenswaarden / Valeurs Limites (Belgium, 11/2011). TWA: 5 mg/m ³ 8 hours.
2,2'-iminodiethanol	Lijst Grenswaarden / Valeurs Limites (Belgium, 6/2007). Absorbed through skin. TWA: 2 mg/m ³ 8 hours. TWA: 0.46 ppm 8 hours.
molybdenum trioxide	Lijst Grenswaarden / Valeurs Limites (Belgium, 11/2011). Notes: as Mo TWA: 10 mg/m ³ , (as Mo) 8 hours.
Bulgaria  2,2'-iminodiethanol	РБ МТСП и МЗ Наредба №13/2003 (Bulgaria, 8/2007). Absorbed through skin. Limit value 8 hours: 10 mg/m ³ 8 hours.
molybdenum trioxide	България Министерство на труда и социалната политика и Министерството на здравеопазването (Bulgaria, 1/2012). Limit value 8 hours: 10 mg/m ³ , (as Molybdenum) 8 hours.
Croatia	

SECTION 8: Exposure controls/personal protection

propane-1,2-diol	MinGoRP GVI/KGVI (Croatia, 1/2009). ELV: 150 ppm 8 hours. ELV: 10 mg/m ³ 8 hours. Form: particulates ELV: 474 mg/m ³ 8 hours. Form: total vapour and particulates
molybdenum trioxide	MinGoRP GVI/KGVI (Croatia, 1/2009). ELV: 10 mg/m ³ , (as Mo) 8 hours.
Czech Republic	
2,2',2''-nitritoltriethanol	MZCR PEL/NPK-P (Czech Republic, 2/2012). Absorbed through skin. STEL: 10 mg/m ³ 15 minutes. STEL: 1.64 ppm 15 minutes. TWA: 5 mg/m ³ 8 hours. TWA: 0.82 ppm 8 hours.
2,2'-iminodiethanol	178/2001 (Czech Republic, 12/2007). STEL: 10 mg/m ³ 15 minutes. STEL: 2.32 ppm 15 minutes. TWA: 5 mg/m ³ 8 hours. TWA: 1.16 ppm 8 hours.
molybdenum trioxide	MZCR PEL/NPK-P (Czech Republic, 2/2012). Notes: as Mo STEL: 25 mg/m ³ , (as Mo) 15 minutes. TWA: 5 mg/m ³ , (as Mo) 8 hours.
Denmark	
2,2',2''-nitritoltriethanol	Arbejdstilsynet (Denmark, 10/2012). TWA: 3.1 mg/m ³ 8 hours. TWA: 0.5 ppm 8 hours.
2,2'-iminodiethanol	Arbejdstilsynet (Denmark, 3/2008). Absorbed through skin. TWA: 2 mg/m ³ 8 hours. TWA: 0.46 ppm 8 hours.
molybdenum trioxide	Arbejdstilsynet (Denmark, 10/2012). Notes: calculated as Mo TWA: 10 mg/m ³ , (calculated as Mo) 8 hours.
Estonia	
2,2',2''-nitritoltriethanol	Sotsiaalminister (Estonia, 10/2007). Skin sensitizer. STEL: 10 mg/m ³ 15 minutes. TWA: 5 mg/m ³ 8 hours.
2,2'-iminodiethanol	Sotsiaalminister (Estonia, 10/2007). Absorbed through skin. STEL: 30 mg/m ³ 15 minutes. STEL: 6 ppm 15 minutes. TWA: 15 mg/m ³ 8 hours. TWA: 3 ppm 8 hours.
Finland	
2,2',2''-nitritoltriethanol	Työterveyslaitos, Sosiaali- ja terveysministeriö (Finland, 12/2011). TWA: 5 mg/m ³ 8 hours.
2,2'-iminodiethanol	Työterveyslaitos, Sosiaali- ja terveysministeriö (Finland, 8/2007). Absorbed through skin. TWA: 2 mg/m ³ 8 hours. TWA: 0.46 ppm 8 hours.
molybdenum trioxide	Työterveyslaitos, Sosiaali- ja terveysministeriö (Finland, 12/2011). Notes: calculated as Mo TWA: 0.5 mg/m ³ , (calculated as Mo) 8 hours.
France	
2,2'-iminodiethanol	INRS (France, 12/2007). Notes: indicative exposure limits TWA: 15 mg/m ³ 8 hours. TWA: 3 ppm 8 hours.
Germany	
No exposure limit value known.	
Greece	

SECTION 8: Exposure controls/personal protection

2,2'-iminodiethanol	PD 90/1999 (Greece, 8/2007). TWA: 15 mg/m ³ 8 hours. TWA: 3 ppm 8 hours.
molybdenum trioxide	Υπουργείο Εργασίας και Κοινωνικών Υποθέσεων (Greece, 2/2012). Notes: as Mo TWA: 15 mg/m ³ , (as Mo) 8 hours.
Hungary	
molybdenum trioxide	25/2000. (IX. 30.) EüM-SzCsM együttes rendelet (Hungary, 12/2011). Notes: as Mo PEAK: 60 mg/m ³ , (as Mo) 15 minutes. TWA: 15 mg/m ³ , (as Mo) 8 hours.
Ireland	
2,2',2''-nitrilotriethanol	NAOSH (Ireland, 5/2010). OELV-8hr: 5 mg/m ³ 8 hours.
2,2'-iminodiethanol	NAOSH (Ireland, 8/2007). OELV-8hr: 15 mg/m ³ 8 hours. OELV-8hr: 3 ppm 8 hours.
propane-1,2-diol	NAOSH (Ireland, 5/2010). OELV-8hr: 10 mg/m ³ 8 hours. Form: particulate OELV-8hr: 470 mg/m ³ 8 hours. Form: vapour and particulates OELV-8hr: 150 ppm 8 hours. Form: vapour and particulates
molybdenum trioxide	NAOSH (Ireland, 5/2010). Notes: as Mo OELV-8hr: 3 mg/m ³ , (as Mo) 8 hours. Form: Respirable fraction
Italy	
No exposure limit value known.	
Latvia	
sebacic acid	Ministru kabineta - AER (Latvia, 2/2011). TWA: 4 mg/m ³ 8 hours.
benzotriazole	Ministru kabineta - AER (Latvia, 2/2011). TWA: 5 mg/m ³ 8 hours.
propane-1,2-diol	Ministru kabineta - AER (Latvia, 2/2011). TWA: 7 mg/m ³ 8 hours.
Lithuania	
2,2',2''-nitrilotriethanol	Lietuvos Higienos Normos HN 23 (Lithuania, 10/2007). Skin sensitiser. STEL: 10 mg/m ³ 15 minutes. TWA: 5 mg/m ³ 8 hours.
sebacic acid	Lietuvos Higienos Normos HN 23 (Lithuania, 10/2007). TWA: 4 mg/m ³ 8 hours.
2,2'-iminodiethanol	Del Lietuvos Higienos Normos (Lithuania, 10/2007). Absorbed through skin. STEL: 30 mg/m ³ 15 minutes. STEL: 6 ppm 15 minutes. TWA: 15 mg/m ³ 8 hours. TWA: 3 ppm 8 hours.
propane-1,2-diol	Lietuvos Higienos Normos HN 23 (Lithuania, 10/2007). TWA: 7 mg/m ³ 8 hours.
molybdenum trioxide	Lietuvos Higienos Normos HN 23 (Lithuania, 10/2007). TWA: 5 mg/m ³ 8 hours. Form: alveolar TWA: 10 mg/m ³ 8 hours. Form: respirable
Netherlands	
No exposure limit value known.	
Norway	

SECTION 8: Exposure controls/personal protection

2,2',2''-nitrilotriethanol	Arbeidstilsynet (Norway, 12/2011). TWA: 5 mg/m ³ 8 hours.
2,2'-iminodiethanol	Arbeidstilsynet (Norway, 11/2007). TWA: 15 mg/m ³ 8 hours. TWA: 3 ppm 8 hours.
propane-1,2-diol	Arbeidstilsynet (Norway, 12/2011). TWA: 79 mg/m ³ 8 hours. TWA: 25 ppm 8 hours.
molybdenum trioxide	Arbeidstilsynet (Norway, 12/2011). Notes: calculated as Mo TWA: 10 mg/m ³ , (calculated as Mo) 8 hours.
Poland	
2,2'-iminodiethanol	Ministra Pracy i Polityki Społecznej (Poland, 9/2007). TWA: 9 mg/m ³ 8 hours.
molybdenum trioxide	Rozporządzenie Ministra Pracy i Polityki Społecznej (Dz. U. 2002 Nr 217, poz. 1833, z późn. zm.) (Poland, 12/2011). Notes: calculated as Mo STEL: 10 mg/m ³ , (calculated as Mo) 15 minutes. TWA: 4 mg/m ³ , (calculated as Mo) 8 hours.
Portugal	
2,2',2''-nitrilotriethanol	Instituto Português da Qualidade (Portugal, 3/2007). TWA: 5 mg/m ³ 8 hours.
2,2'-iminodiethanol	Instituto Português da Qualidade (Portugal, 3/2007). Absorbed through skin. TWA: 2 mg/m ³ 8 hours.
molybdenum trioxide	Instituto Português da Qualidade (Portugal, 3/2007). Notes: expressed as Mo TWA: 10 mg/m ³ , (expressed as Mo) 8 hours. Form: inhalable fraction TWA: 3 mg/m ³ , (expressed as Mo) 8 hours. Form: respirable fraction
Romania	
molybdenum trioxide	Ministerul Muncii, Familiei si Protectiei Sociale și Ministerul Sănătății (Romania, 1/2012). VLA: 5 mg/m ³ 8 hours. Short term: 10 mg/m ³ 15 minutes.
Slovakia	
2-Propenoic acid, homopolymer, sodium salt	Nariadenie vlády Slovenskej republiky (Slovakia, 12/2011). TWA: 5 mg/m ³ 8 hours. Form: compact aerosols
molybdenum trioxide	Nariadenie vlády Slovenskej republiky (Slovakia, 12/2011). Notes: as Mo TWA: 10 mg/m ³ , (as Mo) 8 hours. Form: inhalable fraction Nariadenie vlády Slovenskej republiky (Slovakia, 12/2011). TWA: 5 mg/m ³ , (as Mo) 8 hours. Form: respirable fraction
Slovenia	
2,2',2''-nitrilotriethanol	Pravilnik o varovanju delavcev pred tveganji zaradi izpostavljenosti kemičnim snovem pri delu (Slovenia, 12/2010). TWA: 5 mg/m ³ 8 hours. Form: inhalable fraction
2,2'-iminodiethanol	Uradni list Republike Slovenije (Slovenia, 6/2007). Absorbed through skin. TWA: 15 mg/m ³ 8 hours. Form: inhalable fraction
Spain	
2,2',2''-nitrilotriethanol	INSHT (Spain, 1/2012). TWA: 5 mg/m ³ 8 hours.
2,2'-iminodiethanol	INSHT (Spain, 1/2008). Absorbed through skin. TWA: 2 mg/m ³ 8 hours. TWA: 0.46 ppm 8 hours.
molybdenum trioxide	INSHT (Spain, 1/2012). Notes: as Mo TWA: 10 mg/m ³ , (as Mo) 8 hours. Form: inhalable fraction INSHT (Spain, 1/2012). TWA: 3 mg/m ³ , (as Mo) 8 hours. Form: respirable fraction

SECTION 8: Exposure controls/personal protection**Sweden**

2,2',2''-nitritoltriethanol

AFS 2011:18 (Sweden, 12/2011). Absorbed through skin.STEL: 10 mg/m³ 15 minutes.TWA: 5 mg/m³ 8 hours.

STEL: 1.6 ppm 15 minutes.

TWA: 0.8 ppm 8 hours.

2,2'-iminodiethanol

AFS 2005:17 (Sweden, 6/2007). Absorbed through skin.STEL: 30 mg/m³ 15 minutes.

STEL: 6 ppm 15 minutes.

TWA: 15 mg/m³ 8 hours.

TWA: 3 ppm 8 hours.

molybdenum trioxide

AFS 2011:18 (Sweden, 12/2011).TWA: 5 mg/m³, (as Mo) 8 hours. Form: respirable dust**AFS 2011:18 (Sweden, 12/2011). Notes: as Mo**TWA: 10 mg/m³, (as Mo) 8 hours. Form: total dust**Switzerland**

2,2',2''-nitritoltriethanol

SUVA (Switzerland, 1/2013).STEL: 20 mg/m³ 15 minutes. Form: Inhalable dust (total dust)TWA: 5 mg/m³ 8 hours. Form: Inhalable dust (total dust)

2,2'-iminodiethanol

SUVA (Switzerland, 1/2007). Absorbed through skin. Skin sensitiser. Notes: not temporary

TWA: 1 ppm 8 hours. Form: inhalable dust

SUVA (Switzerland, 1/2007). Absorbed through skin. Skin sensitiser.

STEL: 1 ppm 15 minutes. Form: inhalable dust

molybdenum trioxide

SUVA (Switzerland, 1/2013). Notes: calculated as MoTWA: 10 mg/m³, (calculated as Mo) 8 hours. Form: Inhalable dust (total dust)**Turkey**

2,2'-iminodiethanol

NIOSH REL (United States, 6/2008).TWA: 15 mg/m³ 10 hours.

TWA: 3 ppm 10 hours.

United Kingdom (UK)

propane-1,2-diol

EH40/2005 WELs (United Kingdom (UK), 12/2011).TWA: 10 mg/m³ 8 hours. Form: ParticulateTWA: 474 mg/m³ 8 hours. Form: Sum of vapour and particulates

TWA: 150 ppm 8 hours. Form: Sum of vapour and particulates

molybdenum trioxide

EH40/2005 WELs (United Kingdom (UK), 12/2011). Notes: as MoSTEL: 20 mg/m³, (as Mo) 15 minutes.TWA: 10 mg/m³, (as Mo) 8 hours.

Recommended monitoring procedures : If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

Derived effect levels

No DELs available.

Predicted effect concentrations

No PECs available.

SECTION 8: Exposure controls/personal protection

8.2 Exposure controls

Appropriate engineering controls : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

Hygiene measures : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles. Recommended: safety glasses with side-shields

Skin protection

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated. < 1 hour (breakthrough time): disposable vinyl

Body protection : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. Recommended: overall

Other skin protection : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection : Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator. Recommended: None assigned.

Environmental exposure controls : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state : Liquid.

Colour : Colourless to light yellow.

Odour : Faint

pH : 7.3

Melting point/freezing point : Not available.

Initial boiling point and boiling range : Not available.

Flash point : Not available.

Upper/lower flammability or explosive limits : Not available.

Relative density : 1.175

Solubility(ies) : Easily soluble in the following materials: cold water and hot water.

Partition coefficient: n-octanol/ water : Not available.

Auto-ignition temperature : Not available.

SECTION 9: Physical and chemical properties

VOC content

4.3 % (w/w)

9.2 Other information

No additional information.

SECTION 10: Stability and reactivity**10.1 Reactivity** : No specific test data related to reactivity available for this product or its ingredients.**10.2 Chemical stability** : The product is stable.**10.3 Possibility of hazardous reactions** : Under normal conditions of storage and use, hazardous reactions will not occur.**10.4 Conditions to avoid** : No specific data.**10.5 Incompatible materials** : No specific data.**10.6 Hazardous decomposition products** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.**SECTION 11: Toxicological information****11.1 Information on toxicological effects**Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
benzotriazole	LD50 Oral	Rat	560 mg/kg	-
molybdenum trioxide	LD50 Oral	Rat	188 mg/kg	-

Conclusion/Summary : Not available.

Route	ATE value

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
benzotriazole	Eyes - Severe irritant	Rabbit	-	100 milligrams	-

Conclusion/Summary : Not available.Sensitiser**Conclusion/Summary** : Not available.Mutagenicity**Conclusion/Summary** : Not available.Carcinogenicity**Conclusion/Summary** : Not available.Reproductive toxicity**Conclusion/Summary** : Not available.Teratogenicity**Conclusion/Summary** : Not available.**Information on the likely routes of exposure** : Not available.Potential acute health effects

SECTION 11: Toxicological information

- Inhalation** : Exposure to decomposition products may cause a health hazard. Serious effects may be delayed following exposure.
- Ingestion** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Eye contact** : Irritating to eyes.

Symptoms related to the physical, chemical and toxicological characteristics

- Inhalation** : No specific data.
- Ingestion** : No specific data.
- Skin contact** : No specific data.
- Eye contact** : Adverse symptoms may include the following:
irritation
watering
redness

Delayed and immediate effects and also chronic effects from short and long term exposure**Short term exposure**

- Potential immediate effects** : Not available.

- Potential delayed effects** : Not available.

Long term exposure

- Potential immediate effects** : Not available.

- Potential delayed effects** : Not available.

Potential chronic health effects

Not available.

- Conclusion/Summary** : Not available.
- General** : No known significant effects or critical hazards.
- Carcinogenicity** : No known significant effects or critical hazards.
- Mutagenicity** : No known significant effects or critical hazards.
- Teratogenicity** : No known significant effects or critical hazards.
- Developmental effects** : No known significant effects or critical hazards.
- Fertility effects** : No known significant effects or critical hazards.
- Other information** : Not available.

SECTION 12: Ecological information**12.1 Toxicity**

Product/ingredient name	Result	Species	Exposure
2,2'-iminodiethanol	Acute LC50 2150 µg/l Fresh water	Daphnia - Daphnia pulex	48 hours
	Acute LC50 100000 µg/l Fresh water	Fish - Pimephales promelas - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
molybdenum trioxide	Chronic NOEC 540 ppm Marine water	Fish - Cyprinodon variegatus - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Acute LC50 203.2 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours
	Acute LC50 70000 µg/l Fresh water	Fish - Pimephales promelas	96 hours

- Conclusion/Summary** : Not available.

12.2 Persistence and degradability

- Conclusion/Summary** : Not available.

12.3 Bioaccumulative potential

SECTION 12: Ecological information

Not available.

12.4 Mobility in soilSoil/water partition coefficient (K_{oc}) : Not available.

Mobility : Not available.

12.5 Results of PBT and vPvB assessment

PBT : Not applicable.

vPvB : Not applicable.

12.6 Other adverse effects : No known significant effects or critical hazards.**SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods**Product**

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Waste product residues should not be disposed of via the sewer but processed in a suitable effluent treatment plant. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

Hazardous waste : Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 91/689/EEC.

European waste catalogue (EWC)

Waste code	Waste designation
16 03 06	organic wastes other than those mentioned in 16 03 05

Packaging

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Special precautions : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	IMDG
14.1 UN number	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-

Superconcentrate Protector F1 Box**SECTION 14: Transport information**

14.3 Transport hazard class(es)	-	-
14.4 Packing group	-	-

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture****EU Regulation (EC) No. 1907/2006 (REACH)****Annex XIV - List of substances subject to authorisation****Substances of very high concern**

None of the components are listed.

Annex XVII - Restrictions : Not applicable.
on the manufacture,
placing on the market and
use of certain dangerous
substances, mixtures and
articles

Other EU regulations**Europe inventory** : Not determined.

Product/ingredient name	Carcinogenic effects	Mutagenic effects	Developmental effects	Fertility effects
Boron potassium oxide (B4K2O7), tetrahydrate molybdenum trioxide	- Carc. Cat. 3; R40	- -	Repr. Cat. 3; R63 -	- -

National regulations**Austria**

Product/ingredient name	List name	Name on list	Classification	Notes
Molybdenum trioxide	Austria Occupational Exposure Limits	Molybdäntrioxid	Carc. B	-

Belgium**Bulgaria****Croatia****Czech Republic****Denmark****Estonia****Finland****France****Germany****Hazard class for water** : 1 Appendix No. 4**Greece****Hungary****Ireland****Italy****Latvia****Lithuania****Netherlands****Norway****Poland****Portugal****Romania**

SECTION 15: Regulatory information[Slovakia](#)[Slovenia](#)[Spain](#)[Sweden](#)[Switzerland](#)[Turkey](#)[United Kingdom \(UK\)](#)**15.2 Chemical Safety Assessment**

: This product contains substances for which Chemical Safety Assessments are still required.

SECTION 16: Other information**Date of printing** 01/10/2014.**Date of issue/ Date of revision** : 26/09/2014.**Date of previous issue** : 25/04/2014.**Version** : 2**Notice to reader**

☐ Indicates information that has changed from previously issued version.

Abbreviations and acronyms : ATE = Acute Toxicity Estimate
 CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
 DNEL = Derived No Effect Level
 EUH statement = CLP-specific Hazard statement
 PNEC = Predicted No Effect Concentration
 RRN = REACH Registration Number

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

☐ Eye Dam. 1, H318

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
☐ Eye Dam. 1, H318	Calculation method

Europe**Full text of abbreviated H statements**

: ☐ H302 Harmful if swallowed.
 H315 Causes skin irritation.
 H318 Causes serious eye damage.
 H319 Causes serious eye irritation.
 H335 May cause respiratory irritation. (Respiratory tract irritation)
 (Respiratory tract irritation)
 H351 Suspected of causing cancer.
 H361fd Suspected of damaging fertility if swallowed. Suspected of damaging the unborn child if swallowed.
 (Fertility and Unborn child)
 (oral)
 H373 May cause damage to organs through prolonged or repeated exposure if swallowed.
 H412 Harmful to aquatic life with long lasting effects.

Superconcentrate Protector F1 Box

Full text of classifications [CLP/GHS]	:  Acute Tox. 4, H302 Aquatic Chronic 3, H412 Carc. 2, H351 Eye Dam. 1, H318 Eye Irrit. 2, H319 Repr. 2, H361fd (Fertility and Unborn child) (oral) Skin Irrit. 2, H315 STOT RE 2, H373 (oral) STOT SE 3, H335 (Respiratory tract irritation)	ACUTE TOXICITY (oral) - Category 4 LONG-TERM AQUATIC HAZARD - Category 3 CARCINOGENICITY - Category 2 SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 1 SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2 TOXIC TO REPRODUCTION (Fertility and Unborn child) (oral) - Category 2 SKIN CORROSION/IRRITATION - Category 2 SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) (oral) - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3
Full text of abbreviated R phrases	:  R40- Limited evidence of a carcinogenic effect. R63- Possible risk of harm to the unborn child. R22- Harmful if swallowed. R48/22- Harmful: danger of serious damage to health by prolonged exposure if swallowed. R41- Risk of serious damage to eyes. R36- Irritating to eyes. R38- Irritating to skin. R36/37- Irritating to eyes and respiratory system. R52/53- Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.	
Full text of classifications [DSD/DPD]	:  Carc. Cat. 3 - Carcinogen category 3 Repr. Cat. 3 - Toxic to reproduction category 3 Xn - Harmful Xi - Irritant	

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

an Alent plc Company